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Abstract
Vaccine or vaccine-reassortant rotavirus strains were detected in fecal specimens from 5 of 106 
(4.7%) immunocompetent children who required treatment for rotavirus gastroenteritis at a large 
pediatric hospital in Texas in 2009–2010. Four strains were related to pentavalent rotavirus 
vaccine, whereas one was related to monovalent rotavirus vaccine. The contribution of these 
strains to each patient’s illness was unclear given that 2 patients had prominent respiratory 
symptoms and 2 were concurrently infected with another pathogen (group F adenovirus and 
norovirus). Continued monitoring is necessary to assess the role of vaccine strains and vaccine-
reassortant strains in pediatric rotavirus infections.
Rotavirus is a nonenveloped, RNA virus belonging to the Reoviridae family [1]. Group A 
rotaviruses, the primary source of human infection, have been genotyped conventionally 
through characterization of the 2 outer capsid proteins, VP7 (G-type) and VP4 (P-type). 
These capsid proteins contribute to regional and temporal diversity of circulating strains [2, 
3].
Two live, attenuated, orally administered vaccines are currently licensed and recommended 
for use in infants: 3-dose pentavalent vaccine (RotaTeq [RV5]; Merck Vaccines), which 
contains 5 G1-G4, and P[8] human-bovine reassortant strains, and 2-dose monovalent 
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vaccine (Rotarix [RV1]; GlaxoSmith-Kline Biologicals), which contains a single human 
G1P[8] strain.
Following vaccination, rotavirus vaccine strains replicate in the gastrointestinal tract and 
may be shed in the stool. In prelicensure trials and 1 postlicensure assessment, viral 
shedding was observed 7 days after the first dose in 25.6%–26.5% of RV1 recipients and in 
8.9%–21.4% of RV5 recipients 1–15 days after any dose [4–6]. Likely transmission of 
vaccine virus from infants given RV1 to their unvaccinated twins was observed in a 
randomized clinical trial [7]. Transmission of RV5 virus through fecal shedding has not 
been formally assessed; however, 1 instance of horizontal transmission of vaccinederived 
virus to an unvaccinated sibling resulting in acute gastroenteritis (AGE) requiring medical 
attention has been described [8].
Rotavirus has the ability to undergo reassortment with wild-type or vaccine-derived strains 
because of its segmented genome [9]. Little is known about the frequency with which 
reassortment occurs or the resulting clinical outcome. This report describes 5 children with 
AGE who were found to be shedding rotavirus vaccine strains and/or vaccine-reassortant 
strains during routine surveillance.
METHODS
Active surveillance for AGE was conducted at Texas Children’s Hospital from November 
2009 through June 2010. Children aged 15 days–4 years with AGE (≥3 episodes of diarrhea 
and/or ≥1 episode of vomiting) requiring emergency department treatment or hospitalization 
were offered enrollment. A questionnaire assessing disease symptoms and epidemiologic 
factors was administered, and fecal specimens were collected within 14 days of illness onset.
Institutional review board approval was obtained from Baylor College of Medicine and 
Texas Department of State Health Services. Informed consent was obtained from 
participants’ parents/guardians.
Fecal specimens were tested for rotavirus antigen using the Premier Rotaclone kit (Meridian 
Bioscience, Inc). RNA was extracted from 10% stool suspensions using the MagNA Pure 
Compact instrument with the MagNA Pure Compact RNA isolation kit (Roche Applied 
Science). VP4 and VP7 genotyping and amplicon sequencing were performed [10], and 
identification of RV5 and RV1 strains was carried out through comparison with vaccine 
strain sequences deposited in GenBank [8]. Identification of RV1 was accomplished also by 
alignment of NSP2 sequence with that obtained by genomic sequencing of RV1 vaccine 
itself (unpublished data). Examination of stool samples by electron microscopy (EM) and 
testing for other agents of gastroenteritis by reverse-transcription polymerase chain reaction 
(RT-PCR), polymerase chain reaction (PCR), and culture were performed as previously 
described [8].
RESULTS
A total of 1133 patients with AGE were enrolled. Fecal specimens were obtained from 997 
subjects (88.0%); 106 of these (10.6%) were rotavirus-positive by RT-PCR. Subsequent 
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genomic sequencing of the 106 rotavirus-positive fecal specimens identified 5 (4.7%) 
patients with vaccine-reassortant and/or vaccine strains. The epidemiologic and clinical 
characteristics of these 5 patients and their virus characterization findings are described 
below.
Patient 1
A previously healthy 22-month-old boy presented with a history of 11 episodes of 
nonbloody, nonbilious emesis occurring over a 2-hour period (Table 1). He was treated with 
oral ondansetron, orally rehydrated, and discharged. The patient returned 8 hours later with 
persistent vomiting. Because he was tachycardic and dehydrated, he received intravenous 
fluids overnight and was discharged the next day. Although the patient had received no 
doses of rotavirus vaccine, his infant sibling received a second dose of RV5 7 days prior to 
the patient’s illness onset.
The VP7 G1 gene of RV5 component strain WI79-9 (G1P [5]) (99.9% identity in 839 bases 
sequenced) and the VP4 P[8] (100% identity in 835 bases) and VP6 I2 (100% identity in 338 
bases) genes from RV5 strain WI79-4 (G6P[8]) (Table 2) were detected in a fecal specimen 
obtained 2 days after illness onset. The VP3 M2 gene matched the sequence of strains 
WI79-4 (G6P[8]), WI78-8 (G3P[5]), and BrB-9 (G4P[5]) (100% identity in 500 bases). The 
strain appears to be a reassortant derived by insertion of the WI79-9 (G1P[5]) G1 gene onto 
a WI79-4 (G6P[8]) backbone. Rotaviruses and unidentified particles 30–40 nm in diameter 
were observed by EM. All other tests were negative.
Patient 2
A 4-month-old boy presented with a 4-day history of rhinorrhea and nonbloody diarrhea, 
and 3 days of fever. The patient was wheezing and tachypneic with an oxygen saturation of 
95%. He was diagnosed with bronchiolitis, treated with levalbuterol and vaponephrine, and 
observed overnight. The patient received his first dose of RV5 11 days before illness onset.
Genetic analysis of a fecal specimen obtained 9 days after illness onset detected the VP7 G1 
gene of RV5 strain WI79-9 (G1P[5]) (100% identity in 854 bases) and the VP4 P[8] gene 
from RV5 strain WI79-4 (G6P[8]) (100% identity in 835 bases) (Table 2). The VP6 I2 gene 
detected matched that of RV5 component strains WI79-9 (G1P[5]), SC2-9 (G2P[5]), 
WI78-8 (G3P[5]), and BrB-9 (G4P[5]) (100% identity in 342 bases). The VP3 M2 gene 
matched the sequence of strains WI79-4 (G6P[8]), WI78-8 (G3P[5]), and BrB-9 (G4P[5]) 
(100% identity in 500 bases). This strain appears to be a double reassortant with either the 
WI79-9 (G1P[5]) VP7 and VP6 genes inserted onto a WI79-4 (G6P[8]) backbone or the VP4 
of WI79-4 (G6P[8]) and VP3 of WI79-4 (G6P[8]), BrB-9 (G4P[5]), or WI78-8 (G3P[5]) 
inserted onto a WI79-9 (G1P [5]) backbone. Rotaviruses and adenoviruses were observed by 
EM. Real-time PCR was positive for adenovirus group F; all other tests were negative.
Patient 3
A previously healthy 2-month-old girl presented with 4 days of vomiting and 2 days of 
fever, cough, and conjunctivitis without diarrhea. On physical exam, she was fussy but 
consolable with mild conjunctival injection and nasal discharge. Laboratory evaluation 
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revealed an elevated white blood cell count (19 700/μL) with 12% bandemia. Urinalysis and 
urine culture were negative. The patient was treated with intravenous ceftriaxone and 
discharged. She received her first dose of RV5 1 day before illness onset.
A fecal specimen was obtained 5 days after illness onset and appeared to contain 
nonreassortant RV5 component strain BrB-9 (G4P[5]) alone. The VP7 G4 gene of BrB-9 
(G4P[5]) was detected (100% identity in 363 bases) along with VP4 P [5] (100% identity in 
416 bases), VP6 I2 (100% identity in 342 bases), and VP3 M2 genes (100% identity in 500 
bases) consistent with BrB-9 (G4P[5]). By EM, a few unidentified 30-nm particles were 
observed; all other tests were negative.
Patient 4
A previously healthy 2-month-old boy presented with 3 days of nonbloody diarrhea and 2 
days of fever and irritability. On physical exam, he was fussy but consolable with a slightly 
distended abdomen and hyperactive bowel sounds. Negative laboratory examinations 
included complete blood count with differential, urinalysis, and urine culture (catheterized). 
The patient was orally rehydrated and discharged. He received his first dose of RV5 2 days 
before illness onset.
Four distinct VP7 genotypes were detected in a specimen obtained 3 days after illness onset: 
the G1 gene of RV5 component strain WI79-9 (G1P[5]) (100% identity in 116 bases); the 
G2 gene of strain SC2-9 (G2P[5]) (100% identity in 202 bases); the G4 gene of strain BrB-9 
(G4P[5]) (100% identity in 363 bases); and the G6 gene of strain WI79-4 (G6P[8]) (99.8% 
identity in 421 bases) (Table 2). The VP4 P[8] gene (99.9% identity in 835 bases) and VP6 
I2 (100% identity in 342 bases) genes from RV5 strain WI79-4 (G6P[8]) were detected. The 
VP3 M2 gene matched the sequence of strains WI79-4 (G6P [8]), WI78-8 (G3P[5]), and 
BrB-9 (G4P[5]) (100% identity in 500 bases). This specimen appears to contain 4 strains, 
the WI79-4 (G6P[8]) component strain itself and 3 potential reassortant strains each 
composed of strain WI79-4 (G6P[8]) but expressing G1, G2, and G4 individually. 
Rotaviruses were observed by EM, and real-time RT-PCR was positive for norovirus 
genogroup II. All other tests were negative.
Patient 5
A 6-month-old boy presented with a 1-day history of nonbloody, nonbilious vomiting with 
diarrhea, lethargy, and fever. His past medical history was notable for failure-to-thrive and 
gastroesophageal reflux. The patient’s 2.5-year-old sister also had been ill with vomiting. On 
physical exam, he was tachycardic and had generalized pallor. The patient failed oral 
rehydration and was subsequently treated with intravenous ondansetron and fiuids and was 
observed overnight. Neither the patient nor his sister had received any doses of either 
rotavirus vaccine.
Analyses of a fecal specimen obtained 8 days after illness onset identified what appears to 
be an RV1-derived strain. Sequences of the VP7 (850 bases), VP4 (803 bases), and NSP2 
(991 bases) genes each shared 99.8% identity with cognate RV1 vaccine strain sequences. 
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Rotaviruses and unidentified particles 40–45 nm in diameter were observed by EM. All 
other tests were negative.
DISCUSSION
These patients illustrate a spectrum of potential clinical and virologic outcomes associated 
with routine use of live, attenuated rotavirus vaccines. The diversity of these occurrences 
include apparent transmission of an RV5 vaccine-reassortant strain from a vaccinated infant 
to an unvaccinated sibling ( patient 1); detection of an RV5 vaccine-reassortant strain in a 
recently vaccinated child ( patient 2); detection of a nonreassortant RV5 vaccine strain in a 
recently vaccinated child ( patient 3); detection of an RV5 vaccine strain and 3 potential 
vaccine-reassortant strains in a recently vaccinated child ( patient 4); and detection of an 
RV1 vaccine strain in an unvaccinated child residing in an area with low RV1 coverage 
( patient 5).
Although these findings suggest potentially unusual transmission or vaccine replication 
processes, the contribution of the vaccine or vaccine-reassortant strain to each patient’s 
illness is unclear. Patient 1’s illness was clinically consistent with rotavirus AGE and 
occurred after exposure to a younger sibling who had recently received RV5. This patient’s 
history of exposure and subsequent illness is similar to a prior report of sibling transmission 
of the same vaccine-derived G1P[8] strain [8], supporting the likely linkage between this 
vaccine-reassortant strain and patient 1’s illness. Patients 2 and 3 had upper respiratory 
symptoms accompanied by vomiting or diarrhea, and their illnesses were less typical of 
rotavirus disease alone. Additionally, detection of adenovirus group F in patient 2’s 
specimen provides a plausible alternate etiology. Similarly, although patient 4 had diarrhea 
without respiratory symptoms, the presence of norovirus genogroup II in his fecal specimen 
along with the potential vaccine-reassortant strains makes it impossible to discern the cause 
of his illness. The presence of multiple reassortant RV5 strains in patient 4’s stool is very 
unusual, and these findings will be confirmed using an advanced genetic characterization 
method such as microarray analysis and/or deep sequencing. Both patient 5 and his 2.5-year-
old sister presented with symptoms consistent with rotavirus disease. The RV1 strain 
detected in this unvaccinated patient’s stool is suggestive of an environmental exposure to a 
vaccine strain that is not widely present in the patient’s community. Although RV1 uptake 
rates in the Houston area during this surveillance period are not known, no enrolled patient 
received any doses of RV1, thus confirming its rare use. However, because a full 
epidemiologic investigation was not conducted, it is impossible to determine how this 
patient’s exposure to RV1 occurred or the role of RV1 in the patient’s illness. These 
outcomes highlight the difficulty in establishing clear causative relationships between 
vaccine-derived strains and clinical illness, despite exhaustive laboratory testing.
The detection of rotavirus vaccine or vaccine-derived reassortant strains in fecal specimens 
from 5 of 106 (4.7%) immunocompetent, rotavirus-positive children hospitalized or visiting 
the emergency department with AGE symptoms was surprising. Although the population 
rate of severe AGE related to vaccine or vaccine-reassortant strains is likely to be low given 
the large number of vaccinated children and their contacts residing in the catchment area of 
our surveillance hospital, such events may not be as uncommon as previously suspected. 
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Continued monitoring is necessary to assess the rate of occurrence and clinical relevance of 
vaccine strains and vaccine-reassortant strains in symptomatic and asymptomatic pediatric 
rotavirus infections.
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